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Abstract: Several initiatives at establishing a classification of inherited metabolic disorders have been
published previously, some focusing on pathomechanisms, others on clinical manifestations, while yet an-
other attempted a simplified approach of a comprehensive nosology. Some of these classifications suffered
from shortcomings, such as lack of a mechanism for continuous update in light of a rapidly‐evolving field,
or lack of widespread input from the metabolic community at large. Our classification – the Interna-
tional Classification of Inherited Metabolic Disorders, or ICIMD – includes 1,450 disorders, and differs
from prior approaches in that it benefited from input by a large number of experts in the field, and was
endorsed by major metabolic societies around the globe. Several criteria such as pathway involvement
and pathomechanisms were considered. The main purpose of the hierarchical, group‐based approach of
the ICIMD is an improved understanding of the interconnections between many individual conditions
that may share functional, clinical and diagnostic features. The ICIMD aims to include any primary
genetic condition in which alteration of a biochemical pathway is intrinsic to specific biochemical, clinical
and/or pathophysiological features. As new disorders are discovered, we will seek the opinion of experts
in the advisory board prior to inclusion in the appropriate group of the ICIMD, thus guaranteeing the
continuing relevance of this classification via regular curation and expert advice.
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Several initiatives at establishing a classification of inherited metabolic disorders have been 
published previously, some focusing on pathomechanisms, others on clinical manifestations, while 
yet another attempted a simplified approach of a comprehensive nosology. Some of these 
classifications suffered from shortcomings, such as lack of a mechanism for continuous update in 
light of a rapidly-evolving field, or lack of widespread input from the metabolic community at large. 
Our classification – the International Classification of Inherited Metabolic Disorders, or ICIMD – 
includes 1,450 disorders, and differs from prior approaches in that it benefited from input by a large 
number of experts in the field, and was endorsed by major metabolic societies around the globe. 
Several criteria such as pathway involvement and pathomechanisms were considered. The main 
purpose of the hierarchical, group-based approach of the ICIMD is an improved understanding of the 
interconnections between many individual conditions that may share functional, clinical and 
diagnostic features. The ICIMD aims to include any primary genetic condition in which alteration of a 
biochemical pathway is intrinsic to specific biochemical, clinical and/or pathophysiological features. 
As new disorders are discovered, we will seek the opinion of experts in the advisory board prior to 
inclusion in the appropriate group of the ICIMD, thus guaranteeing the continuing relevance of this 
classification via regular curation and expert advice.   












The first attempt at classifying inherited metabolic disorders dates back to 1960, with the publication 
of  the first edition of “The metabolic basis of inherited disease” (Stanbury et al. 1960). In that book, 
ten groups of disorders were defined, affecting the metabolism of carbohydrates, amino acids, lipids, 
steroids, purines and pyrimidines, metals, porphyrins, blood and blood-forming tissues, renal tubular 
transport, and plasma proteins, respectively. Several classification systems have been proposed since 
then, including a classification based on pathomechanisms, in four groups affecting transport, 
scavenging and secretion, synthesis, and intermediary metabolism, respectively (Sinclair 1982). A 
clinical classification is also available, dividing disorders into those involving single organ systems 
versus multisystemic presentations, the latter in turn subdivided into disorders of complex 
molecules, intoxication disorders, and energy deficiency disorders (Saudubray and Charpentier 
2014). A hierarchical classification was established by the Society for the Study of Inborn Errors of 
Metabolism (SSIEM), with groups of disorders assigned according to the specific biochemical 
pathway involved (Zschocke 2014). A recently proposed nosology included greater than one 
thousand well-established diseases and more than 100 provisional ones, divided in 130 groups 
(Ferreira et al. 2019). A practical simplification of this nosology was subsequently suggested 
(Saudubray et al. 2019). 
Why should one bother about structured disease classification at a time of complex electronic 
databases that allow easy access to, and plenty of interconnections between, a large number of 
entries? The primary aim of any classification is probably to structure one’s thoughts and approach in 
order to improve our understanding of large datasets. This is the reasoning behind the “International 
Classification of Inborn Metabolic Disorders” (ICIMD) presented here. It groups almost 1500 
monogenic diseases whose underlying pathophysiology may be regarded as “metabolic” into a 
hierarchical structure that can serve as a basis for didactic purposes (including textbooks and 
seminars), electronic resources, other existing disease databases, patient registries, rare disease 
initiatives, and many other purposes. For registration of affected individuals and epidemiological 
studies it is very important to adhere to a uniform classification. An ontological system makes it 
much easier to understand and remember individual conditions through the knowledge of the 
common clinical features and diagnostic strategies for whole groups of disorders. The primary 
benefit of an ICIMD thus should be for teaching, understanding and clinical decision making with 
regard to inherited metabolic disorders. Given this, the target audience for this classification remains 
the group of physicians and researchers already working in the field of metabolism, although 
practitioners in other fields might benefit as well; for example, we include approximately 70 











disorders of neurotransmission and 50 endocrine metabolic disorders, the hierarchical inclusion of 
which could prove useful to neurologists and endocrinologists, respectively. 
Starting with a kick-off meeting at the Annual Symposium of the Society for the Study of Inborn 
Errors of Metabolism (SSIEM) in Athens 2018, the strategy was to combine knowledge and opinions 
from a large number of stakeholders throughout the world and to seek endorsement by international 
professional societies. The proposed ICIMD was to be combined with existing databases and 
nosologies. A classification is irrelevant if there is no strategy for long-term maintenance, e.g., 
through support of the international scientific community. A broad process with general consensus, 
authorization and maintenance by international societies worldwide, was regarded as the best way 
to create a useful and lasting structure. The result of this process is presented here. 
 
Methods 
Definition of “inherited metabolic disorders” 
We opted to use the nomenclature “inherited metabolic disorders”. Here, we use the term inherited 
to account for traits that have a defined (or assumed) primary genetic cause, regardless of whether 
the genetic material was inherited from a parent or appeared de novo. In the great majority of cases, 
these traits are also inborn, meaning they are present at the time of birth. However, in rare occasions 
we decided to also include somatic diseases, either when they can be associated with abnormalities 
in standard biochemical tests (as is the case with somatic mutations in IDH1 [isocitrate 
dehydrogenase 1] leading to D-2-hydroxyglutaric aciduria), or when these diseases lead to clinical 
manifestations commonly encountered by metabolic physicians (such as for example in the setting of 
hyperinsulinism caused by somatic activating mutations in AKT2 [AKT serine-threonine kinase 2]). 
The term “mutation” is used in this manuscript for genetic variants that have confirmed clinical 
consequences.  
What defines metabolism? We decided to use an inclusive approach, covering any condition in which 
primary alteration of a biochemical pathway is intrinsic to specific biochemical, clinical and/or 
pathophysiological features, regardless of whether there are abnormalities in currently available 
biochemical laboratory tests (Morava et al. 2015).  
We abstained from using the term “errors” in order to avoid negative connotations. The choice 
between diseases and disorders was somewhat more nuanced. The rather broad term “disorder” 
describes basically any deviation from normal physical function, whereas “disease” is usually thought 
to make assumptions about the causation of a clinical phenotype, in line with the notion, for 












example, of histidinaemia as a “non-disease” as lack of histidine ammonia-lyase has no known health 
consequences. However, the clinical consequences of some “diseases” are unclear or unproven (as is 
the case with ACSF3 [Acyl-CoA Synthetase Family Member 3] deficiency causing combined malonic 
and methylmalonic aciduria, Levtova et al. 2019), whereas some apparently harmless traits may have 
clinical effects under specific conditions. Thus, basing the term “disease” on purely clinical criteria is 
difficult. Another approach to the terms “disease” and “disorder” focuses on the knowledge of the 
specific aetiology of a condition. In this concept, any disturbance of the body's normal homeostatic 
processes with a defined cause (such as mutations in a particular gene) is denoted a “disease”, 
whereas the term “disorder” is used for a more general functional abnormality that does not have a 
single precise cause. The metabolic syndrome, for example, is a disorder, not a disease. We have 
decided to combine these definitions for the ICIMD. In this context, “diseases” are defined as 
disturbances of metabolic functions that (a) are clinically significant, i.e., cause clinical symptoms and 
signs at least in certain circumstances, and (b) have a defined cause or pathogenesis, which in the 
context of the ICIMD mostly equates to known or presumed altered function of a single gene 
product. The term “disorder” covers any type of metabolic alteration, regardless of the cause or 
association with clinical manifestations.  
In summary, the ICIMD aims to include any metabolic condition as defined above, irrespective of its 
clinical consequences. In the vast majority of cases the entries represent enzyme deficiencies caused 
by reduced function mutations in single genes, although some conditions are caused by activating 
mutations or by structural genomic alterations (e.g., in the mitochondrial genome). 
Method of generating the ICIMD 
We chose certain criteria when designing our classification system. Different degrees of disease 
severity were considered as a single entity, and not broken down into subtypes. In cases of locus 
heterogeneity (multiple genes associated with the same phenotype) the involvement of each gene 
product was considered as the basis for inclusion. This has consequences for the nomenclature, as in 
these cases, diseases are named by the causative gene product, not by their clinical presentation. 
This is particularly relevant for the syndromic mitochondrial disorders. For example, the disease 
entity “mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes” (MELAS 
syndrome) is not listed in the ICIMD as such but rather by several mt-DNA encoded transfer RNA 
(tRNA) and respiratory chain subunits deficiencies. Leigh syndrome, the most frequently observed 
phenotype of mitochondrial disease in childhood, may be caused by approaching 100 different 
monogenic disorders involving mtDNA-encoded and nuclear genes (Rahman et al. 2017). Future 
revisions of the ICIMD may develop a system of including specific phenotype descriptions associated 
with variants in several genes in an ontological fashion. In cases of allelic heterogeneity (multiple 












phenotypes associated with the same gene), different pathomechanisms were considered necessary 
for separation into different entries. We decided to include disorders (143 in total) even if they 
remain provisional, i.e., have only been reported in a single family so far, or have not been confirmed 
at a molecular level. In many cases, diseases could easily be ascribed to more than one metabolic 
pathway or group; in such instances (about 10% of all disorders in the ICIMD), we selected the 
pathway which we judged most appropriate and cross-referenced diseases in the other group(s). 
Whenever possible, we attempted to use already established metabolic databases (such as the KEGG 
Pathway Database) as the default basis for the ICIMD, but adapted it for clinical purposes where 
necessary. For example, the KEGG database (Kanehisa and Goto 2000) lists the citric acid cycle under 
the category of carbohydrate metabolism, whereas we included it under the category of energy 
substrate metabolism, as this seems more appropriate for clinical and didactic purposes. Similarly, 
glycerol kinase deficiency has previously been included under the category of “disorders of glycolysis 
and the pentose phosphate pathway” (Saudubray et al. 2016), or disorders of glycerol metabolism 
included under the category of lipid disorders (Ferreira et al. 2019) or organic acidurias (McCabe 
2019). Although each of the aforementioned approaches had their own rationale (glycerol is a polyol, 
it is a precursor for the synthesis of triglycerides and glycerophospholipids, and glycerol kinase 
deficiency can be detected by urine organic acid analysis), we decided to include this enzyme 
deficiency under the category of disorders of gluconeogenesis. This is because glycerol kinase 
participates in the conversion of glycerol into a gluconeogenic substrate, and this more easily 
explains the manifestations of hypoglycemia and metabolic acidosis seen in glycerol kinase 
deficiency. This example emphasizes once more our pursuit towards a clinical and didactic goal for 
the ICIMD.  
A representative advisory group was established which included experts involved in previous 
classifications, senior members of international metabolic societies, metabolic journal editors, and 
others based on known expertise in specific disorders. They were asked to provide input on 
delineation of disorder groups at the initial stage of development, as well as to review entries in all 
groups towards the final stage of development of the ICIMD. Endorsement of the final classification 
was obtained from the elected representatives of all international metabolic societies.  
 
Results 
The ICIMD includes 1,450 disorders divided in 24 categories comprising 124 groups (see figure 1). The 
full database can be viewed at www.icimd.org. The first 13 categories comprise the disorders of 












intermediary metabolism. For the purpose of this classification, we defined intermediary metabolism 
as follows:  
a. the full set of reactions that transform nutritive material into energy storage compounds, 
reducing equivalents, and biosynthetic intermediates;  
b. the metabolites involved in these reactions are required to be of low-molecular weight, thus 
excluding macromolecules; and  
c. it is circumscribed to anabolism/catabolism of nutrient small molecules (excluding non-
nutrient ones).  
In other words, disorders of intermediary metabolism involve pathways that mediate the breakdown 
of low-molecular weight nutrient compounds belonging to one of the three major energy substrates 
(proteins, carbohydrates, and lipids) or convert them into substrates for the biosynthesis of complex 
molecules. Intermediary metabolism in the definition used here includes energy metabolism based 
on mitochondrial oxidative phosphorylation which covers categories 5-11 in the ICIMD. We have 
loosely followed the “rational genetic classification” of mitochondrial disorders originally proposed 
by Salvatore DiMauro (DiMauro 2011). This progressively evolved over the years with the discovery 
of new classes of mitochondrial disorders affecting mitochondrial DNA (mtDNA) maintenance and 
gene expression, import, dynamics, cofactor biosynthesis and quality control. We decided to 
separate the mtDNA-related from the nuclear-encoded disorders impacting oxidative 
phosphorylation because of differences in genetic mechanisms, clinical presentation and diagnostic 
approaches. 
Categories 14 and 15 represent disorders of lipid metabolism and transport, whereas the disorders of 
heterocyclic compounds (nucleotides and tetrapyrroles) are listed in categories 16 and 17. Categories 
18-20 comprise disorders affecting the metabolism of complex macromolecules and organelles; they 
include disorders of glycan metabolism (including the congenital disorders of glycosylation but 
excluding disorders of glycogen metabolism), the biogenesis and interaction of organelles, and 
complex molecule degradation (including lysosomal disorders). In contrast to other metabolic 
classifications and textbooks, the ICIMD does not have a single chapter on peroxisomal disorders as 
the enzymes in this organelle have rather diverse functions leading to very different clinical 
presentations. Most peroxisomal disorders affect lipid metabolism and are located in category 14 
whereas peroxisomal biogenesis disorders are listed in the respective category 19. Also in that 
category are the disorders of lysosome-related organelle biogenesis which mostly have a different 
clinical presentation to the other lysosomal disorders.   












Disorders of the metabolism of cofactors and minerals (including vitamins and trace elements) are 
collected in categories 21 and 22. These disorders have the potential to affect multiple 
aforementioned pathways, as they are necessary for a variety of enzymatic (and sometimes non-
enzymatic) reactions. Vitamins and cofactors that are relevant for single pathways only (e.g., 
coenzyme Q10 and lipoic acid in mitochondrial disorders) are positioned in the respective group. 
Finally, disorders of neurotransmitter and endocrine metabolism are provided as disorders of 
metabolic cell signaling in categories 23 and 24. 
The categories are as follows: 
1) Disorders of amino acid metabolism 
This rather large category comprises many of the traditional “metabolic disorders” which are 
identified by standard “metabolic investigations” such as amino acid and organic acid analysis and 
are often amenable to dietary treatment. Deficiencies of enzymes involved in amino acid metabolism 
frequently result in the accumulation of toxic substances and subsequent organ damage. Acute 
symptoms are often associated with catabolic states that lead to the breakdown of endogenous 
proteins. Most groups are based on (common) metabolic pathways of specific amino acids. An 
exception is the group of the organic acidurias which we define as deficiencies of mitochondrial 
enzymes required for the breakdown of coenzyme A (CoA)-activated small carboxylic acids mostly 
resulting from deamination of amino acids. Disorders of amino acid transport are also included here. 
2) Disorders of peptide and amine metabolism 
This small but diverse category covers deficiencies of enzymes involved in the biosynthesis and 
regeneration of glutathione, as well as dipeptidase deficiencies and disorders of methylamine and 
polyamine metabolism. 
3) Disorders of carbohydrate metabolism 
This category includes the disorders of galactose and fructose metabolism; gluconeogenesis, 
glycogen metabolism, and glycolysis; pentose/polyol metabolism; and hexose transmembrane 
transport and absorption. 
4) Disorders of fatty acid and ketone body metabolism 
Clinically, mobilisation of stored triglycerides (lipolysis) during fasting results in the hepatic 
production of ketone bodies which serve as an energy source particularly for muscle and brain, the 
latter with a high energy demand but a limited ability to oxidise fatty acids. Consequently, this 












category includes the disorders of mitochondrial fatty acid oxidation, carnitine metabolism, and 
ketone body synthesis, breakdown and transport. 
5) Disorders of energy substrate metabolism 
The products of amino acid, carbohydrate, and lipid breakdown are transported into the 
mitochondria where they serve as substrates for adenosine triphosphate (ATP) synthesis by the 
process of oxidative phosphorylation. We have combined the disorders of pyruvate metabolism and 
the Krebs cycle as well as creatine metabolism under the term “energy substrate metabolism”; 
however, pyruvate carboxylate deficiency is positioned in the “disorders of gluconeogenesis” group 
because of biochemical functional and clinical reasons. 
6) Mitochondrial DNA-related disorders 
The first mitochondrial disorders defined genetically involved deletions and point mutations of the 
mtDNA. As the mtDNA has a different inheritance pattern to the nuclear genome, and clinical 
expression of pathogenic mtDNA variants is influenced by mtDNA heteroplasmy, biochemical 
threshold for the specific variant and its tissue segregation, we have elected to list the 37 mtDNA-
encoded genes together as one category. Three groups encompass disorders associated with the 13 
protein-coding genes, the genes encoding mitochondrial tRNAs and rRNAs, and the disorders 
associated with single large-scale mtDNA deletions. 
7) Nuclear-encoded disorders of oxidative phosphorylation 
This category includes deficiencies of nuclear-encoded subunit components as well as assembly 
factors of the five oxidative phosphorylation complexes, which are generally (although not invariably) 
associated with isolated deficiency of a single enzyme complex in affected tissue(s). 
8) Disorders of mitochondrial cofactor biosynthesis 
Here we have included disorders affecting the intramitochondrial biosynthesis of the following 
cofactors: coenzyme Q10 (ubiquinone), lipoic acid, iron-sulphur clusters and cytochrome c. These 
disorders have been separated out from the main category of vitamin and cofactor metabolism 
deficiencies because they are expressed exclusively in the mitochondrion. 
9) Disorders of mitochondrial DNA maintenance and replication 
In this category there are two groups: proteins needed for mitochondrial nucleotide pool 
maintenance and those essential for mtDNA replication and maintenance. 
10) Disorders of mitochondrial gene expression 












This rapidly expanding category of now more than 60 conditions includes disorders of mitochondrial 
transcript processing and modification, aminoacyl-tRNA synthetases and the mitoribosome. 
11) Other disorders of mitochondrial function 
In this category we have included disorders of mitochondrial shuttles and carriers (with cross-
referencing to some mitochondrial carriers that are included elsewhere in our classification), 
disorders of mitochondrial protein import, disorders of mitochondrial protein quality control, and 
miscellaneous mitochondrial disorders that do not fit in the above groups, or whose function has not 
been established conclusively. 
12) Disorders of metabolite repair/proofreading 
There is a growing number of diseases affecting metabolite repair or proofreading (Veiga-da-Cunha 
et al. 2020); enzymes deficient in these conditions do not have a function in a particular metabolic 
pathway but remove detrimental metabolites generated as side reactions of other enzymes. As the 
number of these diseases is expected to increase, we felt that they deserve “their own” category. 
13) Miscellaneous disorders of intermediary metabolism 
In this category we included disorders of glyoxylate and oxalate metabolism as these can derive from 
a range of metabolites including amino acids (hydroxyproline, glycine, serine), ascorbic acid, and 
others. In addition, we created a group of unassigned disorders of intermediary metabolism that are 
difficult to locate in any other group. 
14) Disorders of lipid metabolism 
For the classification of disorders of lipid metabolism, we tried to follow as closely as possible an 
already-established and well reputed classification system for lipids, LIPID MAPS® (Fahy et al. 2005, 
2009). Thus, we include groups for disorders of the metabolism of fatty acyls (with peroxisomal fatty 
acid oxidation disorders as a distinct entity), glycerolipids, glycerophospholipids, sphingolipids, and 
sterol lipids (the latter including sterols and bile acids). Fatty acyls include fatty acids, fatty aldehydes, 
and eicosanoids. However, we decided to diverge from this previously established lipid classification 
for didactic purposes, as mitochondrial fatty acid oxidation disorders are better included under 
intermediary metabolism, glycolipids (glycosylphosphatidylinositol and glycosphingolipids) are 
included under the category of congenital disorders of glycosylation, and prenol lipids are included as 
ubiquinones (disorders of coenzyme Q10 biosynthesis under mitochondrial cofactor biosynthesis in 
group 8), vitamin E and K are included under other disorders of vitamin metabolism, and polyprenols 
in disorders of dolichol metabolism under congenital disorders of glycosylation. 












15) Disorders of lipoprotein metabolism 
The disorders that affect lipid transport are divided into different groups based on the type of lipid 
anomalies manifest in the blood, and other functional aspects. They include the 
hypercholesterolemias, hypertriglyceridemias, mixed hyperlipidemias, disorders of high-density 
lipoprotein (HDL) metabolism, disorders with decreased low-density lipoprotein (LDL) and/or 
triglycerides, and other disorders of lipoprotein metabolism.  
16) Disorders of nucleobase, nucleotide and nucleic acid metabolism 
The disorders of pyrimidine and purine metabolism disorders include disorders in the de novo 
synthesis, salvage and breakdown of nitrogenous bases, nucleosides and nucleotides. We then added 
disorders of ectonucleotides and nucleic acids (polymers of nucleotides) as well as non-mitochondrial 
tRNA and rRNA metabolism. 
17) Disorders of tetrapyrrole metabolism 
Under this category we include disorders of porphyrins (heme biosynthetic disorders) as well as 
disorders involving the products of heme breakdown (biliverdin and bilirubin).  Although corrin also 
represents a tetrapyrrole, disorders involving corrin metabolism are discussed elsewhere (as 
disorders of cobalamin metabolism). 
18) Congenital disorders of glycosylation 
Many proteins and lipids require the attachment of carbohydrates to render them functional. The 
Congenital Disorders of Glycosylation (CDG) are divided into disorders affecting N-linked and O-
linked protein glycosylation (including glycosaminoglycan synthesis), disorders of lipid glycosylation 
(including the disorders of glycosylphosphatidylinositol biosynthesis), and disorders with the 
potential to affect multiple glycosylation pathways (dolichol metabolism, Golgi transport and 
homeostasis, sialic acid metabolism, and others).  
19) Disorders of organelle biogenesis, dynamics and interactions 
Disorders that affect the biogenesis and interaction of organelles are usually difficult to link to 
specific metabolic pathways and often cause diverse clinical manifestations. To address this, we 
decided to create a separate category which includes disorders of mitochondrial membrane 
biogenesis and remodelling, mitochondrial and peroxisomal dynamics, peroxisomal biogenesis (the 
peroxin-related peroxisomal disorders), lysosome-related organelle biogenesis, organelle interplay, 
and vesicular trafficking. 
20) Disorders of complex molecule degradation 












This category comprises what is generally known as lysosomal disorders – such as the disorders of 
sphingolipid, glycosaminoglycan, or glycoprotein degradation and the neuronal ceroid lipofuscinoses 
– as well as the disorders of autophagy and some other disorders. 
21) Disorders of vitamin and cofactor metabolism 
Vitamins and cofactors relevant for various metabolic pathways include tetrahydrobiopterin, 
thiamine (vitamin B1), riboflavin (vitamin B2), niacin and nicotinamide (vitamin B3), pantothenate 
(vitamin B5) and coenzyme A, pyridoxine (vitamin B6), biotin (vitamin B7), folate (vitamin B9), 
cobalamin (vitamin B12), molybdenum cofactor, and others. The cofactors coenzyme Q10, lipoic acid 
and iron-sulphur clusters are grouped under mitochondrial disorders. 
22) Disorders of trace elements and metals 
We included disorders of the metabolism of copper, iron, manganese, and zinc.  
23) Neurotransmitter disorders 
The ICIMD contains a specific category of disorders of neurotransmission, given the increased 
attention and scrutiny that these disorders have encountered in the metabolic community in recent 
years (Cortès-Saladelafont et al. 2016; Tristán-Noguero and García-Cazorla 2018). Well known 
“metabolic” neurotransmitter disorders that are recognized by the analysis of cerebrospinal fluid 
affect monoamines and gamma-aminobutyric acid. This category also includes disorders that affect 
the neurotransmitter function of specific amino acids (glutamate, glycine) and choline, as well as 
disorders of the synaptic vesicle cycle. 
24) Endocrine metabolic disorders 
Our last category highlights the link between some metabolic and endocrine disorders. In this 
category we included disorders affecting insulin metabolism (because of the overlap with the clinical 




Classifying a large number of metabolic diseases with a diverse genetic and pathogenic basis and 
almost any imaginable clinical presentation into a single hierarchical structure is an impossible task 
and can only be partially achieved, and only then by cutting many corners. The core unit of the ICIMD 
is the clinical or biochemical phenotype linked to a particular gene that defines a particular 
“monogenic” condition. The different genetically defined diseases are grouped according to 












metabolic pathways which usually share pathogenetic mechanisms and often give rise to related 
clinical presentations and are frequently recognized by the same biochemical-diagnostic strategies. 
Inherited metabolic disorders may be understood and learned by understanding the functional 
consequences of disturbances in different biochemical pathways, and identifying the individual 
disease in a second step. To aid this, we have also mapped ICIMD disorders onto 250 of the 
255 inborn errors of metabolism captured in the Virtual Metabolic Human database (VMH.life) 
(Noronha et al. 2019) as well as to 767 of 3,288 (23%) genes present in the human metabolic 
reconstruction, Recon 3D (Brunk et al. 2018). 
Clearly there are limits to this strategy as the concept of a “monogenic” inheritance pattern is often 
difficult to maintain. Disease manifestation may depend on more than one particular gene, there 
may be more than one causative gene for a clinically and biochemically defined condition, or 
different (e.g., loss-of-function vs. activating) mutations in the same gene may cause very different 
phenotypes. Nevertheless, there are ways to allow for these exceptions, e.g., by defining gene-based 
disease subtypes for conditions that may be caused by mutations in more than one gene. If a disease 
may have quite variable presentation in different patients it is generally regarded as a single 
condition in the ICIMD, regardless of the spectrum of associated severities.  
The main reasoning behind this approach is that within the huge variety of “diseases” linked to 
specific “clinical presentations”, genes and their associated spectrum of clinical phenotypes are 
objective natural entities, reflected in, and linking to, many other genetic databases. Also, gene 
variants have become the main entry point into the diagnosis of rare diseases made by genome-wide 
sequencing technologies. In the new “reverse Medical Genetics” era, it is essential to understand the 
spectrum of clinical effects that variants in the same gene may cause. We therefore argue that a 
gene-/aetiology-centred scaffold logically intertwined with the clinical classification is essential for 
the success of a disease classification. With the ICIMD we have attempted to create a logical, 
hierarchical network of specific genes and specific diseases (encompassing clinical spectra and 
subtypes). In most instances this is a 1:1 relationship, but in some cases there is a 2/3/n:1 or 1:2/3/n 
relationship. This should not be considered a shortcoming of our classification, as long as 
classification users are aware of this approach. Genes, proteins or gene functions are part of 
hierarchical networks or pathways, and the same is true for diseases and disease groups. The 
presentation of these complex relationships should not constitute a problem, as long as the core 
units of “genes” and “disease” provide the essential scaffold. 
The results presented here clearly represent a “work in progress” which presumably – and hopefully 
– will never end. For many metabolic pathways most of the “expected” monogenic conditions have 
by now been identified. However, there is a growing number of “metabolite repair” enzymes that do 












not function in a particular pathway but remove detrimental metabolites generated as side reactions 
of other enzymes (Veiga-da-Cunha et al. 2020). There are still more protein-coding genes in the 
human genome without an associated function or clinical phenotype than known disease-causing 
genes. Moreover, we have not even started to fully appreciate the range of possible clinical 
consequences of mutations in non-protein-coding genes. Every month novel inherited metabolic 
diseases are identified, and it can be expected that additional disease (sub-)groups will need to be 
created in the future. The ICIMD thus does not represent a fixed structure but the current agreement 
of a large number of individuals and international organizations which requires continuous discussion 
and update to make it truly useful. 
The classification has been formally endorsed by the Society for the Study of Inborn Errors of 
Metabolism, SSIEM (www.ssiem.org), the Society for Inherited Metabolic Diseases, SIMD 
(www.simd.org), the Latin American Society of Inborn Errors of Metabolism and Neonatal Screening, 
SLEIMPN (www.sleimpn.org), the Australasian Society for Inborn Errors of Metabolism, ASIEM 
(www.hgsa.org.au/asiem), and the Japan Society of Inherited and Metabolic Diseases, JSIMD 
(http://jsimd.net/). The ICIMD has also been endorsed by the European Reference Network for Rare 
Hereditary Metabolic Disorders, MetabERN (https://metab.ern-net.eu/), is supported by Orphanet 
(www.orpha.net) and IEMbase (www.iembase.org; Lee et al. 2018), and has been adopted by the 
Dutch Diagnosis Registration Metabolic Diseases (DDRMD) registry (www.ddrmd.nl). It is also the 
basis of the latest edition of the Vademecum Metabolicum coat pocket book on the diagnosis and 
treatment of inherited metabolic disorders (Zschocke & Hoffmann 2020).  
We plan to establish and maintain a long-term commission for the continuous revision and update of 
the ICIMD, linked to the international metabolic societies and other public stakeholders. This will 
entail the designation of (teams of) group editors who keep track of new developments for individual 
disease categories or groups, and a general ICIMD commission that confirms suggested extensions 
and decides on future developments. It is planned to designate two or more group editors for each 
of the 23 categories – or possibly individual groups – based on their expertise. Group editors will be 
selected on recommendation of the 75 current members of the ICIMD advisory board, the 
international societies, organisations and initiatives that support the ICIMD, and any interested 
person; suggestions can be sent by email to mail@icimd.org. The general ICIMD steering group that 
approves and integrates any changes shall be appointed or endorsed by the participating 
international societies and organisations. Updates to the ICIMD will be implemented in the dedicated 
website, www.icimd.org, and made available in appropriate forms to the relevant databases such as 
IEMbase or Orphanet. 












We hope that the ICIMD will find a range of uses not just for metabolic specialists but also for 
clinicians and scientists in associated fields as well as students, junior doctors and other professionals 
approaching this dynamic area of genetic medicine.   
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Figure 1. Sunburst chart depicting the hierarchical nature of the International Classification of 
Inherited Metabolic Disorders. The size of each section of the chart is directly proportional to the 
number of disorders in that group. For an interactive version of the chart incorporating a zoom 
function, please refer to www.icimd.org.  
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